Lesion-level longitudinal quantitative imaging software
FDA-cleared clinical software for quantifying radiographic changes in oncology
Software · Cloud SaaSCompany source
Company profile
About AIQ Global
AIQ Solutions is a passionate group of entrepreneurs, scientists, and engineers dedicated to improving treatment outcomes for patients with complex diseases worldwide. The company leverages intellectual property and clinical validation to innovate and change how clinicians manage complex diseases, especially in late-stage cancer care. Their flagship product is an FDA 510(k)-cleared clinical software medical device that analyzes serial radiographic images to quantify changes in regions of interest over time and produces reports intended to support oncologist decision-making. The platform focuses on treatment response heterogeneity and personalized medicine, providing novel information for therapy adjustment and outcome optimization. AIQ Solutions offers cloud-based lesion-level image analysis and reporting services, processing serial PET/CT and other radiographic studies to produce quantitative lesion-level metrics delivered via secure cloud workflows. The company also provides research collaborations and clinical validation support, including biomarker development, retrospective study analysis, and clinical validation of imaging-derived predictive metrics. Their technology integrates AI/ML-driven predictive analytics for treatment response with longitudinal lesion tracking and radiomics analysis. AIQ Solutions serves oncologists, health systems, and research institutions, with expertise spanning imaging biomarker development, quantitative image analysis, and integration of analytics into oncology clinical workflows.
Company description AIQ Global official website
Primary marketMedical Imaging & Radiology
Commercial modelCommercial information available on request
Company presenceLinkedIn
Work at AIQ Global?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- Complex diseases
- Immunotherapy response
- Late-stage cancer
- Oncology
Who it serves
- Academic Medical Centers
- Health Systems
- Oncologists
- Research Institutions
Deployment & integration
Cloud Saas · Embedded deployment with recorded integration context.
Recorded integration context: Cloud-scale research data management and collaboration platforms, Research data management systems.
Geographic context
MarketsUSA · Worldwide
Company sourceOfficial website
Company milestones
Platform expansion
Patent granted for System and method for monitoring multiple lesions (US-12150776-B2), FDA 510(k) clearance for lesion-level longitudinal quantitative imaging software
Partnerships
Recorded partners
- MTEC (Medical Technology Enterprise Consortium)
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
OrthoGrid AI Surgical Guidance System
AI-powered intra-operative surgical guidance for orthopedic procedures
Software · EmbeddedCompany source
RBfracture™
AI-powered fracture and trauma detection on X-ray imaging
Software · Cloud SaaSCompany source
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
Development and validation of a longitudinal soft-tissue metastatic lesion matching algorithm.Physics in medicine and biology · Jul 30, 2021
Clinical validation
Clinical-trial records
No linked records are currently available.
Regulatory
Regulatory records
TRAQinform IQK233998 · 510k · Sep 5, 2024
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
Therapy adjustment and outcome optimization
Treatment response heterogeneity and personalized medicine in cancer care
vRad
Partnership to develop a full suite of software algorithms to enhance the speed and accuracy of bone fracture X-ray studies in teleradiology operations
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
No active leadership profiles are currently listed.
06 · Company updates
Updates from AIQ Global
Recent articles published on AIQ Global's official website.
No Company updates are currently listed.
07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Medical Imaging & Radiology
Companies that apply AI to analyze medical images for diagnostic purposes, workflow optimization, or clinical decision support. Covers general radiology (X-rays, CT scans, MRIs, ultrasounds) across multiple organ systems, as well as specialized imaging in ophthalmology and dermatology.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.